Viking Therapeutics

$6.41
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.10 (+1.60%) Today

+$0.05 (+0.79%) As of 8:00 PM EST after-hours

Why Robinhood?

You can buy or sell VKTX and other stocks, options, and ETFs commission-free!

About VKTX

Viking Therapeutics, Inc. Common Stock, also called Viking Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The company's clinical program VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA. The listed name for VKTX is Viking Therapeutics, Inc. Common Stock.

CEO

Brian Lian

Employees

Headquarters

San Diego, California

Founded

2012

Market Cap

463.97M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

1.21M

High Today

$6.43

Low Today

$6.25

Open Price

$6.26

Volume

1.02M

52 Week High

$8.87

52 Week Low

$3.26

Collections

Analyst Ratings

100%

of 14 ratings

Buy

100%

Hold

Sell

VKTX Earnings

-$0.15

-$0.10

-$0.05

$0.00

Q1 FY19

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Feb 24, After Hours